文献速递银屑病与炎症性皮肤病

古塞奇尤单抗对比阿达木单抗持续治疗中重度银屑病:VOYAGE 1 III期试验

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
PubMed 文献 · J Am Acad Dermatol · 2017-01-02

VOYAGE 1为III期双盲、安慰剂及阳性对照试验,将中重度银屑病患者随机分入古塞奇尤单抗100mg组、安慰剂转古塞奇尤单抗组或阿达木单抗组,治疗观察至48周。结果显示古塞奇尤单抗在IGA 0/1与PASI 90上均优于安慰剂和阿达木单抗,患者报告结局改善,不良事件率组间相当。

要点

  • 古塞奇尤单抗第16周IGA 0/1和PASI 90均显著优于安慰剂与阿达木单抗。
  • 疗效优势持续至第48周,患者报告结局同步改善。
  • 不良事件率与对照治疗相当,48周内耐受性良好。

核心结论

  • 古塞奇尤单抗治疗中重度银屑病1年疗效优于阿达木单抗且耐受性良好。
  • 古塞奇尤单抗在医师报告和患者报告结局上均显示优于对照的持续获益。

研究设计与样本

  • III期双盲、安慰剂及阳性对照试验(VOYAGE 1),治疗观察48周。
  • 随机分组:古塞奇尤单抗100mg组n=329;安慰剂转古塞奇尤单抗组n=174;阿达木单抗组n=334。
  • 古塞奇尤单抗给药为第0、4周,之后每8周;阿达木单抗第0周80mg、第1周40mg,之后每2周40mg至第47周。

主要发现

  • 第16周IGA 0/1:古塞奇尤单抗85.1% vs 安慰剂6.9%(P < .001)。
  • 第16周PASI 90:古塞奇尤单抗73.3% vs 安慰剂2.9%(P < .001)。
  • 第16周IGA 0/1与PASI 90:古塞奇尤单抗85.1% vs 阿达木单抗65.9%、73.3% vs 49.7%(P < .001)。
  • 第24周IGA 0/1与PASI 90:古塞奇尤单抗84.2% vs 阿达木单抗61.7%、80.2% vs 53.0%(P < .001)。
  • 第48周IGA 0/1与PASI 90:古塞奇尤单抗80.5% vs 阿达木单抗55.4%、76.3% vs 47.9%(P < .001)。

关键数值与推荐

  • 主要疗效指标为IGA 0/1(清除/最轻)与PASI 90(较基线改善≥90%)。
  • 患者报告结局采用皮肤病生活质量指数(DLQI)与银屑病症状和体征日记评估至第48周。
  • 安全性评估至第48周,各治疗组不良事件率相当。

临床怎么用

  • 对中重度银屑病需长期系统治疗者,古塞奇尤单抗可作为优于阿达木单抗的IL-23阻断选择。
  • 评估疗效可同时采用IGA 0/1、PASI 90及患者报告结局,关注48周内的持续应答。

局限性

  • 分析仅限48周,缺乏更长期数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. OBJECTIVES: We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis treated for 1 year. METHODS: Patients were randomized to guselkumab 100 mg (weeks 0 and 4, then every 8 weeks; n = 329); placebo→guselkumab (weeks 0, 4, and 12 then guselkumab at weeks 16 and 20, then every 8 weeks; n = 174); or adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47; n = 334). Physician-reported outcomes (Investigator Global Assessment, Psoriasis Area and Severity Index [PASI]), patient-reported outcomes (Dermatology Life Quality Index, Psoriasis Symptoms and Signs Diary), and safety were evaluated through week 48. RESULTS: Guselkumab was superior (P < .001) to placebo at week 16 (85.1% vs 6.9% [Investigator Global Assessment score of 0/1 (cleared/minimal)] and 73.3% vs 2.9% [90% or greater improvement in PASI score from baseline (PASI 90)]). Guselkumab was also superior (P < .001) to adalimumab for Investigator Global Assessment 0/1 and PASI 90 at week 16 (85.1% vs 65.9% and 73.3% vs 49.7%), week 24 (84.2% vs 61.7% and 80.2% vs 53.0%), and week 48 (80.5% vs 55.4% and 76.3% vs 47.9%). Furthermore, guselkumab significantly improved patient-reported outcomes through week 48. Adverse event rates were comparable between treatments. LIMITATIONS: Analyses were limited to 48 weeks. CONCLUSIONS: Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1 year.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017. PMID: 28057360. doi:10.1016/j.jaad.2016.11.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。